-
2020 ASCO GU | Urothelial Cancer: Preliminary Results of Phase III EV-301 Study Announced
Time of Update: 2021-03-25
Background The survival rate of patients with locally advanced or metastatic urothelial cancer after treatment with platinum-containing chemotherapy and PD-1/PD-L1 inhibitors is low.
Reference: Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.
-
Wei Qiang, Professor TOMBAL: Frontiers of Clinical Data and Practice of Enzalutamide
Time of Update: 2021-03-25
The approval of the indication for enzalutamide nmCRPC marks a major progress in this devastating disease, and provides a new and meaningful treatment option for doctors and patients with castration-resistant prostate cancer (CRPC).
-
2021 ASCO GU | Interpretation by Professor Sheng Xinan: Progress in the treatment of advanced urothelial cancer
Time of Update: 2021-03-25
However, several randomized controlled phase 3 clinical studies have not been successful, which means that the first-line treatment of advanced urothelial cancer is still platinum-based chemotherapy; and for people who cannot tolerate platinum, immunotherapy can be used as the first-line Treatment options.
-
A full-on urinary tract symptoms: How does diabetic bladder disease occur?
Time of Update: 2021-03-25
Abnormal urothelium affects lower urinary tract function by changing the release of diabetic bladder media and the excitability of sensory nerve fibers, causing detrusor instability and changes in bladder capacity.
The treatment goals of diabetic bladder disease include alleviating LUTS, promoting urinary control, and preserving renal function.
-
Prof. Liping Xie and Prof. Junhua Zheng: Prospects for prostate cancer screening and treatment in the era of precision medicine
Time of Update: 2021-03-25
Compared with the United States and other developed countries, the overall survival rate of prostate cancer patients in my country is poor, and more effective screening and diagnosis and treatment strategies are urgently needed to improve the prognosis of patients.
-
Nature Cell Biology: Single cell analysis reveals the mechanism of human prostate cancer progression
Time of Update: 2021-03-25
Recently, researchers have analyzed the transcriptomes of 36,424 single cells from 13 types of prostate tumors and identified epithelial cells to explain the underlying disease invasion mechanism.
Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression.
-
ASCO GU 2021: The effect of DPP4 inhibitors on PFS in patients with diabetes and prostate cancer
Time of Update: 2021-03-25
Further subgroup analysis showed that the use of DPP4 inhibitors was associated with improved PFS after radiotherapy in patients with diabetes and prostate cancer (4.
-
BMJ Sub-Journal: Chinese scholars have found that drinking more coffee reduces the risk of prostate cancer in men. Drinking more cups a day reduces the risk by 1%
Time of Update: 2021-03-25
To study the association between coffee intake and prostate cancer risk, the research team searched a database of related cohort studies published as of September 2020.
In general, this study shows that increased coffee consumption may be related to lowering the risk of prostate cancer.
-
Application of fluorescence in situ hybridization in the detection of transitional cell carcinoma of the bladder: a multi-center clinical study based on the Chinese population
Time of Update: 2021-03-24
The detection sensitivity and specificity of FISH and cytology in patients with or without a history of cell carcinoma were 84.
Although cytology has better specificity than FISH, this study found that 2 patients had negative cystoscopy results, but the FISH test results at the 4th and 6th months were positive (false positive).
-
Highlights of the 2021 ASCO GU Conference | Everything you missed is here~
Time of Update: 2021-03-24
(⇊Click to see more exciting content) 2021 ASCO GU | Professor Sheng Xinan Interpretation: Research Progress in Late-line Treatment of Advanced Renal Cancer 05 Advanced Urothelial Carcinoma The treatment of advanced urothelial carcinoma (mUC) has achieved breakthroughs in recent years, immunotherapy, targets Drugs conjugated to treatment and antibody have been successful.
-
For mHSPC patients with combined hypertension or metabolic diseases, early use of apatamine therapy can quickly reduce PSA levels and protect them for | Classic case
Time of Update: 2021-03-24
After two high-risk/high-tumor-burden mHSPC patients received apatamide treatment, their PSA levels dropped rapidly, with significant curative effects and good treatment safety.
In case 2, apatamide was used directly in the mHSPC stage, and the PSA level of the patient dropped by >90% after 2 months of treatment, showing a significant effect.
-
[Phase 3] Standardized Diagnosis and Treatment Courses for Prostate Cancer——Progress in Research on Prostate Cancer Surgery
Time of Update: 2021-03-24
The third phase of "Prostate Cancer Standardized Diagnosis and Treatment Course" The third phase is "Prostate Cancer Surgery Research Progress" brought by Professor Chen Wei from the First Affiliated Hospital of Wenzhou Medical University: Click to watch the highlights video!
-
Guidelines·Evidence-based·Practice│Analysis of the first-line choice of new endocrine drugs for mCRPC treatment in multiple dimensions
Time of Update: 2021-03-23
The 2020 CSCO Guidelines for the Diagnosis and Treatment of Prostate Cancer 2 recommends abiraterone acetate for the first-line treatment of mCRPC patients (level I recommendation; 1A evidence) (Figure 1).
-
[2021 ASCO-GU] Going ahead | ACIS study of dual inhibition of new endocrine therapy
Time of Update: 2021-03-23
The hierarchical analysis of the preset subgroups suggests that patients aged ≥75 years, visceral metastases, glandular cavity type by PAM50 test, and AR activity at an average level or above can be treated from apatamide + abiraterone + There are further clinical benefits in prednisone combination therapy.
-
2021 ASCO-GU｜TITAN final survival data update!
Time of Update: 2021-03-23
Figure 1 Professor Kim Chi of BC Cancer in Canada conducted this online sharing TITAN study reveals the huge benefits of early application of new antiandrogenic treatments for mHSPC patients▎apatamide significantly prolongs OS, reduces the overall risk of death by 35%, and early treatment gains In the final analysis this year, apatamide showed a huge therapeutic benefit compared to the control group.
-
How effective are various new endocrine therapy drugs used in nmCRPC?
Time of Update: 2021-03-23
01Abstract 101: The efficacy of enzalutamide compared with apatamide, dalotamide and bicalutamide for nmCRPC delays the progression of nmCRPC to mCRPC and prolongs patient survival, which is the main goal of nmCRPC therapy.
-
Sci Rep: The effect of salt reduction on the control of overactive bladder symptoms
Time of Update: 2021-03-23
The researchers evaluated data from the Overactive Bladder Symptom Score (OABSS) questionnaire and frequency-volume diagrams (FVCs), and estimated daily salt intake by measuring urine sodium and creatinine concentrations using drip urine samples.
-
[2021 ASCO-GU] See the micro-knowledge | SPARTAN studies the correlation between molecular characteristics and long-term efficacy
Time of Update: 2021-03-23
Abstract 8: The correlation between the molecular characteristics of apatamide in the treatment of NM-CRPC and the long-term efficacy [1] SPARTAN study [2] is a global multi-center, randomized, double-blind, placebo-controlled phase III clinical trial, evaluation The effectiveness and safety of apatamide + androgen deprivation therapy (ADT) in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC).
-
[2021 ASCO-GU] It's a natural fit | The final analysis of apatamide in the treatment of mHSPC
Time of Update: 2021-03-23
*For medical professionals' reference only, the 2021 American Society of Clinical Oncology Symposium on Urogenital Oncology (ASCO-GU) will be held on February 11-13, US Central Time. This conference
-
[2021 ASCO-GU] Multi-swords and Combinations | Combination Therapy: A powerful tool for the treatment of prostate cancer?
Time of Update: 2021-03-22
*Only for medical professionals to read for reference. From February 11 to 13, 2021, the American Society of Clinical Oncology Symposium on Urogenital Cancer (ASCO-GU 2021) was successfully held on
